Periodic Reporting for period 4 - MegaALS (Unravelling the Interplay between Metabolism, Gut Microbiome and Adaptive Immunity in Amyotrophic Lateral Sclerosis)
Periodo di rendicontazione: 2023-05-01 al 2024-10-31
1. What is the problem/issue being addressed?
Amyotrophic lateral sclerosis (ALS) is now recognized as a systemic disease affecting both the central nervous system (CNS) and whole-body physiology. Understanding its etiology requires investigating CNS interactions with other physiological systems. MegaALS therefore aims to understand how energy metabolism and immune response alterations contribute to ALS and whether targeting these changes could offer therapeutic potential.
2. Why is it important for society?
ALS is a fatal neurodegenerative disease that affects motor neurons, leading to loss of muscle control and, ultimately, respiratory failure within 1-3 years. With no cure or effective treatment, it remains one of the most devastating diagnoses.
The lack of successful ALS therapies stems from our limited understanding of its etiology. While some susceptibility genes have been identified, their overall contribution appears weak. Established risk factors include older age, male sex, and family history. Identifying additional disease contributors is crucial for advancing prevention strategies and discovering new therapeutic targets.
3. What are the overall objectives?
MegaALS aims to advance disease prevention and identify novel therapeutic targets by exploring the interplay between metabolism, gut microbiome, and adaptive immunity in ALS. It has two key objectives:
I. To reveal the complex interplay between metabolism, gut microbiome, and adaptive immunity in ALS, using comprehensive proteomic, metagenomic and immune-response profiling, through contrasting ALS patients of different clinical phenotypes with their disease-free full siblings, spouses and population-controls.
II. To test the effectiveness of an intervention - a high-caloric diet in combination with fecal microbiota transplant from healthy donors - in delaying disease onset and ameliorating progression, and to test if immune modulation contributes to such effect, using an established transgenic ALS mouse model.
Conclusion of Action
MegaALS has made important contributions to the understanding of ALS as a systematic disease by exploring the interplay between metabolism, gut microbiome and the immune system. Therefore, this project has provided new insights into the disease ethicology and potential therapeutic targets for ALS.
Key findings include:
1. Immune System Contributes to ALS Progression:
I. Certain immune cell subsets, including CD4+ effector T cells and regulatory T cells, were identified as prognostic markers for disease progression and survival.
II. Clonal expansion of T cells in the CNS suggests intrathecal antigen presentation as a potential immune-driven disease mechanism.
2. Biomarker Discoveries:
I. Higher cholesterol levels (total and LDL-C) and specific lipid ratios were linked to risk of mortality after ALS diagnosis.
II. Several clinical chemistry markers (e.g. albumin, neurofilament light chain, leukocyte count) were found to correlate with ALS survival outcomes.
3. Gut Microbiota and ALS:
I. ALS patients exhibited distinct gut microbiota compositions, which were associated with disease prognosis.
II. Fecal microbiota transplantation (FMT) from ALS patients into SOD1 transgenic mice accelerated disease onset and progression, suggesting a causal role for gut microbiota in ALS pathology.
4. Therapeutic Implications:
I. A high-caloric diet (HCD) increased body weight in ALS mice but did not improve disease progression; in some cases, it worsened inflammatory burden.
II. The combination of FMT and dietary interventions demonstrated potential for modulating disease progression, but further research is needed to optimize beneficial microbiota transplantation strategies.
In sum, MegaALS has had a significant scientific and societal impact. It has advanced ALS research by contributing to new therapeutic strategies, particularly in the areas of immune modulation. The identification of biomarkers and the role of the immune system in ALS progression could pave the way for personalized medicine approaches, ultimately improving patient care. Additionally, the project has played a crucial role in training the next generation of ALS researchers. Another key achievement is the buildup of the ALSrisc Study, which will continue to provide unique and high-quality data for future ALS research.
Furture directions include the continued exploration of immune-based therapies, with a particular focus on targeting T cell responses. Research will also focus on the refinement of dietary and microbiota interventions to optimize their therapeutic potential. Additionally, we will expand on multi-omics research for ALS, which will facilitate biomarker discovery and clinical translation.
Amyotrophic lateral sclerosis (ALS) is now recognized as a systemic disease affecting both the central nervous system (CNS) and whole-body physiology. Understanding its etiology requires investigating CNS interactions with other physiological systems. MegaALS therefore aims to understand how energy metabolism and immune response alterations contribute to ALS and whether targeting these changes could offer therapeutic potential.
2. Why is it important for society?
ALS is a fatal neurodegenerative disease that affects motor neurons, leading to loss of muscle control and, ultimately, respiratory failure within 1-3 years. With no cure or effective treatment, it remains one of the most devastating diagnoses.
The lack of successful ALS therapies stems from our limited understanding of its etiology. While some susceptibility genes have been identified, their overall contribution appears weak. Established risk factors include older age, male sex, and family history. Identifying additional disease contributors is crucial for advancing prevention strategies and discovering new therapeutic targets.
3. What are the overall objectives?
MegaALS aims to advance disease prevention and identify novel therapeutic targets by exploring the interplay between metabolism, gut microbiome, and adaptive immunity in ALS. It has two key objectives:
I. To reveal the complex interplay between metabolism, gut microbiome, and adaptive immunity in ALS, using comprehensive proteomic, metagenomic and immune-response profiling, through contrasting ALS patients of different clinical phenotypes with their disease-free full siblings, spouses and population-controls.
II. To test the effectiveness of an intervention - a high-caloric diet in combination with fecal microbiota transplant from healthy donors - in delaying disease onset and ameliorating progression, and to test if immune modulation contributes to such effect, using an established transgenic ALS mouse model.
Conclusion of Action
MegaALS has made important contributions to the understanding of ALS as a systematic disease by exploring the interplay between metabolism, gut microbiome and the immune system. Therefore, this project has provided new insights into the disease ethicology and potential therapeutic targets for ALS.
Key findings include:
1. Immune System Contributes to ALS Progression:
I. Certain immune cell subsets, including CD4+ effector T cells and regulatory T cells, were identified as prognostic markers for disease progression and survival.
II. Clonal expansion of T cells in the CNS suggests intrathecal antigen presentation as a potential immune-driven disease mechanism.
2. Biomarker Discoveries:
I. Higher cholesterol levels (total and LDL-C) and specific lipid ratios were linked to risk of mortality after ALS diagnosis.
II. Several clinical chemistry markers (e.g. albumin, neurofilament light chain, leukocyte count) were found to correlate with ALS survival outcomes.
3. Gut Microbiota and ALS:
I. ALS patients exhibited distinct gut microbiota compositions, which were associated with disease prognosis.
II. Fecal microbiota transplantation (FMT) from ALS patients into SOD1 transgenic mice accelerated disease onset and progression, suggesting a causal role for gut microbiota in ALS pathology.
4. Therapeutic Implications:
I. A high-caloric diet (HCD) increased body weight in ALS mice but did not improve disease progression; in some cases, it worsened inflammatory burden.
II. The combination of FMT and dietary interventions demonstrated potential for modulating disease progression, but further research is needed to optimize beneficial microbiota transplantation strategies.
In sum, MegaALS has had a significant scientific and societal impact. It has advanced ALS research by contributing to new therapeutic strategies, particularly in the areas of immune modulation. The identification of biomarkers and the role of the immune system in ALS progression could pave the way for personalized medicine approaches, ultimately improving patient care. Additionally, the project has played a crucial role in training the next generation of ALS researchers. Another key achievement is the buildup of the ALSrisc Study, which will continue to provide unique and high-quality data for future ALS research.
Furture directions include the continued exploration of immune-based therapies, with a particular focus on targeting T cell responses. Research will also focus on the refinement of dietary and microbiota interventions to optimize their therapeutic potential. Additionally, we will expand on multi-omics research for ALS, which will facilitate biomarker discovery and clinical translation.
In addition to the above mentioned key results, MegaALS has created valuable scientific outputs that can benefit future research and the development of new treatment strategies.
Potential clinical application includes a) the identification of immune and metabolic biomarkers for prognosis prediction and patient stratification, b) the discovery of clonally expanded T cells in the central nervous system of patients, shedding light on potential immune targets and T cell based immunotherapy, as well as c) microbiota-targeted treatments, including dietary interventions.
In addition, MegaALS supported the buildup of the ALSrisc Study, which is becoming an increasingly rich data source for ALS research. The ALSrisc Study includes today more than 500 ALS cases and more than 300 controls with both in-depth data on disease phenotypes, risk factors, and various biomarkers. The biological specimens collected in ALSrisc Study build the foundation of future multi-omics analysis with the purposing of identifying better biomarkers for the risk and prognosis of ALS.
The findings of MegaALS have been actively disseminated to academic, clinical, and public audiences through high-impact scientific publications, conferences, and outreach activities. A complete list of all scientific publications is shown in the section below. In addition, research conducted in MegaALS have been constantly presented at leading ALS conferences, including ENCALS, MND/ALS Symposium, and Keystone Symposium on Neuro-Immune Interactions. Furthermore, MegaALS has supported the training of future ALS researchers including nine PhD theses, among which majority of the PhD graduates transitioned into postdoctoral research, continuing ALS research and expanding international collaborations.
In conclusion, MegaALS has provided important insights into our understanding of ALS as a disease, with significant implications for diagnosis, prognosis, and therapy development. By establishing new research resources, training the next generation of ALS scientists, and engaging in widespread dissemination efforts, MegaALS has made a lasting impact on ALS research and clinical care. The findings from this project will continue to contribute to future ALS research and support therapeutic strategies.
Potential clinical application includes a) the identification of immune and metabolic biomarkers for prognosis prediction and patient stratification, b) the discovery of clonally expanded T cells in the central nervous system of patients, shedding light on potential immune targets and T cell based immunotherapy, as well as c) microbiota-targeted treatments, including dietary interventions.
In addition, MegaALS supported the buildup of the ALSrisc Study, which is becoming an increasingly rich data source for ALS research. The ALSrisc Study includes today more than 500 ALS cases and more than 300 controls with both in-depth data on disease phenotypes, risk factors, and various biomarkers. The biological specimens collected in ALSrisc Study build the foundation of future multi-omics analysis with the purposing of identifying better biomarkers for the risk and prognosis of ALS.
The findings of MegaALS have been actively disseminated to academic, clinical, and public audiences through high-impact scientific publications, conferences, and outreach activities. A complete list of all scientific publications is shown in the section below. In addition, research conducted in MegaALS have been constantly presented at leading ALS conferences, including ENCALS, MND/ALS Symposium, and Keystone Symposium on Neuro-Immune Interactions. Furthermore, MegaALS has supported the training of future ALS researchers including nine PhD theses, among which majority of the PhD graduates transitioned into postdoctoral research, continuing ALS research and expanding international collaborations.
In conclusion, MegaALS has provided important insights into our understanding of ALS as a disease, with significant implications for diagnosis, prognosis, and therapy development. By establishing new research resources, training the next generation of ALS scientists, and engaging in widespread dissemination efforts, MegaALS has made a lasting impact on ALS research and clinical care. The findings from this project will continue to contribute to future ALS research and support therapeutic strategies.
The MegaALS research program has made significant contribution to the literature on ALS research. These contributions are described above and have been published. The full list of all publications, including manuscripts can be found in the attached files (MegaALS_Publication and MegaALS_Publication_2). None of the manuscripts are in press.